

ARTIFICIAL INTELLIGENCE & DRUG DISCOVERY

Evolution Global's latest timeline infographic explores Big Pharma's investment into the burgeoning field of AI-driven drug design and discovery.

2013

Exscientia
DRIVEN BY KNOWLEDGE

 **sunovion**

janssen 

April: Exscientia signs proof-of-concept deal with Sunovion.

July: Exscientia establishes collaboration with Janssen R&D.

2014

BenevolentAI

 **CHAMPIONS**
ONCOLOGY

Lilly



March: Exscientia announces bispecific drug discovery agreement with Sumitomo Dainippon Pharma.

June: Numerate completes \$8m financing round co-led by Eli Lilly Ventures.

BenevolentAI announces partnership with an unnamed major US pharmaceutical company to develop novel Alzheimer's medicines, potentially worth over \$800m+

November: Exscientia partners with Sunovion to collaborate on the discovery and optimisation of novel medicines for psychiatric disorders in a deal worth \$4.8m.

Insilico Medicine and Champions Oncology announce research collaboration on drug discovery and in silico drug efficacy evaluation in oncology.

2015

 **Atomwise**
Better medicines faster.

MERCK

June: Atomwise raises \$6m in seed funding, and announces collaborations with Merck, Notable Labs and Harvard Medical School.

September: Exscientia reaches first delivery milestone in collaboration with Sumitomo Dainippon.

2016

 **evotec**

 **RECURSION**

SANOFI 

April: Evotec and Exscientia announce partnership to discover bispecific small molecule immune-oncology therapeutics. Recursion Pharmaceuticals announces research agreement with Sanofi Genzyme to deploy its drug repurposing platform to identify new uses for clinical stage molecules across dozens of genetic diseases.

November: BenevolentAI enters exclusive license agreement with Janssen for clinical stage AI-evaluated drug candidates.

2017

 **BERG**

twoXAR
Santen

 **gsk**

AstraZeneca 
JUVENESCENCE

Numerate


February: BERG initiates phase I/II monotherapy trial for its AI-selected drug candidate BPM 31510-IV for the treatment of glioblastoma multiforme. Santen and twoXAR announce strategic research collaboration to discover new glaucoma treatments.

March: Insilico and GSK announce strategic collaboration to enhance the development and manufacture of candidate vaccines.

April: BenevolentAI agrees 2-year partnership with MRC Technology to explore drug discovery initiatives in the field of small molecules and antibodies.

June: Numerate and Takeda enter agreement to generate novel clinical candidates using AI-driven drug discovery.

July: Exscientia & GSK enter strategic drug discovery collaboration worth up to \$43m.

August: Insilico and Juvenescence sign multi-year drug development agreement to advance compounds discovered using AI. BERG forms research collaboration with AstraZeneca to identify new therapeutic targets to treat neurological disorders.

September: Evotec invests €15m in Exscientia (immuno-oncology).



EVOLUTION
GLOBAL TALENT ATTRACTION



EVOLUTION
BIOSCIENCE